Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)

NCT06569212 is registered in ClinicalTrials.gov with Madeleine Puissant as lead sponsor.

NCT NCT06569212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06569212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)
Lead sponsor
Madeleine Puissant
Phase
Phase 4
Overall status
Recruiting
Start date
September 23, 2024
Completion date
September 30, 2029
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-traumatic subarachnoid hemorrhage